@article{TCR11960,
author = {Rene Hoffstetter and Ismael Riquelme and Alejandra Andana and Carmen G. Ili and Kurt Buchegger and Hernán Vargas and Priscilla Brebi and Juan Carlos Roa},
title = {Evaluation of DNA methylation in promoter regions of SFRP4 and ZAR1 in urine and plasma of women with cervical lesions},
journal = {Translational Cancer Research},
volume = {6},
number = {1},
year = {2017},
keywords = {},
abstract = {Background: Aberrant DNA hypermethylation in tumor suppressor genes is a common feature in cervical cancer (CC). This abnormal hypermethylation could be used as potential biomarkers for detecting CC in non-invasive samples such as urine and plasma.
Methods: This study aimed to evaluate in urine and plasma the methylation status of two genes previously found hypermethylated in CC (ZAR1 and SFRP4) and assesses their diagnostic value. Thus, DNA methylation was measured in 171 paired samples of urine and plasma taken from women with non-lesions [60], low-grade squamous intraepithelial lesions (L-SIL) [40], high-grade squamous intraepithelial lesions (H-SIL) [40] and cervical squamous cell carcinoma (SCC) [31] by quantitative methylation-specific PCR (QMSP).
Results: In urine, a significant difference was observed for methylation levels of SFRP4 between cancer group and all the other groups (P},
issn = {2219-6803}, url = {https://tcr.amegroups.org/article/view/11960}
}